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Introduction
Thrombus formation due to platelet adherence to ruptured 
plaques plays a pivotal role in the pathogenesis of acute coro-
nary syndrome (ACS) and myocardial infarction [1]. Moreover, 
platelet aggregation induces the release of secondary messengers 
that are responsible for further thrombus formation and vaso-
constriction [2]. Accordingly, dual antiplatelet therapy (DAPT) 
consisting of aspirin and a P2Y12 inhibitor, mainly clopidogrel, 
has become the cornerstone of medical therapy for ACS [3]. The 
role of DAPT is even more important during the re-endothelial-
ization period after percutaneous coronary intervention (PCI), 
during which time thrombotic risk is greatest due to endothelial 
injury by ballooning or stent coverage [4].
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With the unavoidable interference in the coagulation cas-
cade, however, DAPT is accompanied by an inevitable increase 
in bleeding risk, even in patients not exposed to surgical proce-
dures [5]. In this context, surgery not only exposes the patients 
to additional bleeding risk but also exposes them to an increased 
risk of thrombosis due to the development of hypercoagulabil-
ity during the early postoperative period as a result of systemic 
inflammation [6,7]. Unfortunately, approximately 5–20% of 
patients undergoing PCI are presented for non-cardiac surgery 
within the first 2 years after PCI [8]. Of these, 47% who received 
a drug-eluting stent (DES) were presented for surgery within 12 
months, during which time previous guidelines, based on first-
generation DES, mandated the requirement for DAPT [9]. Thus, 
anesthesiologists are often required to participate in critical 
decision making regarding the continuation/discontinuation of 
DAPT. Ideally, the consensus among the anesthesiologist, cardi-
ologist, surgeon, and patient on perioperative DAPT should be 
individually tailored to minimize both ischemic and bleeding 
risks.
The most widely used P2Y12 inhibitor, clopidogrel, exhibits 
variable inter-individual platelet inhibitory responses [10]. Ac-
cumulating evidence suggests a close association between high 
(on-treatment) platelet reactivity (HPR, less inhibition by the 
drug) and adverse ischemic outcomes [11]. To overcome these 
limitations, newer P2Y12 inhibitors (prasugrel, ticagrelor) have 
been developed with improved pharmacodynamic profiles 
exhibiting more consistent platelet inhibition, although accom-
panying bleeding risks have also increased [12]. As emerging 
data show improved ischemic benefits in selected ACS patients 
treated with prasugrel or ticagrelor versus clopidogrel [13,14], 
anesthesiologists will increasingly encounter these medications. 
In addition, short-acting, reversible antiplatelet agents have be-
come available in intravenous (IV) forms with potential value 
as bridge therapy to surgery [15,16]. In the context of technical 
advances in coronary stents, accumulating evidence regarding 
non-first-generation DES suggests a decreased risk of throm-
botic complications compared to first-generation DES, and a 
reduced necessary duration of DAPT after stent placement [17].
Together with accumulating clinical evidence using the 
newer P2Y12 inhibitors, prasugrel and ticagrelor, in 2016, the 
American College of Cardiology (ACC)/American Heart As-
sociation (AHA) suggested novel recommendations for periop-
erative management timing of non-cardiac surgery in patients 
treated with PCI and DAPT [18]. This review article addresses 
evolving evidence regarding the abovementioned issues to assist 
clinicians in making consensus decisions regarding periopera-
tive DAPT in patients undergoing non-cardiac surgery.
Antiplatelet Therapy
While DAPT consists of aspirin and a P2Y12 inhibitor, cur-
rently available antiplatelet agents can be broadly classified into 
five types based on their mechanism of action in hindering 
platelet aggregation: cyclooxygenase (COX)-1 inhibitor (aspirin), 
P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor), 
glycoprotein (GP) IIb/IIIa inhibitors (abciximab, eptifibatide, 
tirofiban), phosphodiesterase-III inhibitors (dipyridamole, 
cilostazol), and protease-activated receptor-1 inhibitor (vora-
paxar). The use of cilostazol is mainly limited to patients with 
peripheral artery disease [19], and only limited data are available 
regarding the efficacy of triple therapy consisting of DAPT plus 
cilostazol in patients with coronary artery disease without any 
added increase in bleeding risk [20]. Similarly, there is emerg-
ing but limited evidence regarding the use of vorapaxar in ad-
dition to DAPT in patients with coronary artery disease, and 
ischemic benefits have been reported in patients with previous 
myocardial infarction or peripheral artery disease, and diabetes 
[21]. Cilostazol is only a weak, reversible platelet inhibitor with 
an elimination half-life of approximately 21 h, and thus requires 
discontinuation for 2 days before surgery [19]. On the other 
hand, vorapaxar has a long termination half-life of approxi-
mately 126–269 h [12]. Nonetheless, with the limited availability 
of clinical data, the use of cilostazol or vorapaxar will not yet be 
an issue for ACS patients undergoing surgery, as they will only 
Table 1. Clinical Pharmacology of Aspirin, P2Y12 Inhibitors, and Glycoprotein IIb/IIIa Inhibitors
Administration route/mode of action Onset/elimination half-life
% inhibition of  
platelet function
Recovery after 
discontinuation
Aspirin Oral/irreversible cyclooxgenase-1 inhibitor 20–45 min/2–4 h 60–70% 5 days
Clopidogrel Oral/irreversible P2Y12 inhibitor 12–24 h/4–6 h 60–70% 5–7 days
Prasugrel Oral/irreversible P2Y12 inhibitor 0.5–4 h/7 h 90% 7–10 days
Ticagrelor Oral/reversible P2Y12 inhibitor 0.5–4 h/7 h 90% 3–5 days
Cangrelor Intravenous/reversible P2Y12 inhibitor Immediate/3–5 min > 90% 30–60 min
Abciximab Intravenous/reversible glycoprotein IIb/IIIa inhibitor Immediate/10–30 min ~100% 12 h
Tirofiban Intravenous/reversible glycoprotein IIb/IIIa inhibitor Immediate/2–2.5 h ~100% 4 h
Eptifibatide Intravenous/reversible glycoprotein IIb/IIIa inhibitor Immediate/2–2.5 h ~100% 4 h
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be used as an adjunct to DAPT on rare occasions. Thus, their 
pharmacology and anesthetic implications will not be discussed 
further in this review. The pharmacology of GP IIb/IIIa inhibi-
tors will be briefly discussed with regard to their potential use as 
a bridge to surgery [15].
Information regarding the elimination half-life of each 
antiplatelet agent will help in deciding the timing of platelet 
transfusion in patients presenting for emergent surgery with 
continuation DAPT (Table 1). In cases of significant periopera-
tive bleeding under such conditions, the logical approach would 
be transfusion of platelet concentrates. However, if the timing 
of transfusion falls within the 1–2 elimination half-life of the 
antiplatelet agent from its last administration, newly transfused 
platelets will likely be affected by the antiplatelet agent as well, 
and transfusion may need to be repeated.
COX-1 inhibitor, aspirin
Aspirin was the first antiplatelet agent to show clinical ben-
efits in patients with acute myocardial infarction [22]. Studies 
also showed that low-dose aspirin treatment led to a consis-
tent risk reduction in vascular events, including myocardial 
infarction and stroke by 25–30%; therefore, it has become the 
foundation of antiplatelet therapy for ACS [23]. In conjunction, 
recommendations or guidelines of various societies mandate 
the indefinite continuation of aspirin, if possible, when used for 
secondary prevention (recurrence of cardiovascular disease), 
particularly in patients with coronary artery disease [18,24]. It is 
noteworthy that aspirin’s ability to prevent cardiovascular events 
for primary prophylaxis (i.e., in the absence of established car-
diovascular disease) is unclear without any definitive mortality 
benefits [23].
Aspirin is an irreversible COX-1 inhibitor that blocks sub-
sequent thromboxane production for the entire lifespan of 
platelets (usually 7–10 days) [25]. It is able to inhibit 60–70% of 
platelet function, and is rapidly absorbed after oral ingestion, re-
sulting in a > 90% reduction of thromboxane levels. In addition, 
aspirin induces non-thromboxane-dependent effects, including 
enhanced fibrinolysis via acetylation of fibrinogen [26]. In the 
clinical dose range of 75–100 mg, the elimination half-life of 
aspirin is approximately 2–4 h. Aspirin inactivates the COX-1 of 
mature megakaryocytes [27], which are responsible for platelet 
production in the bone marrow. Thus, COX-1 activity may not 
return to normal levels for approximately 48 h after discontinu-
ation. Nonetheless, healthy bone marrow is able to replace 10% 
of the circulating platelets each day. Assuming a normal platelet 
count, discontinuation of aspirin will lead to the production of 
more than 30% of healthy unaffected platelets after 3–4 days, 
which is usually sufficient for normal hemostasis. Indeed, plate-
let aggregation significantly recovers after 2–3 days of aspirin 
discontinuation with complete recovery occurring after 5 days 
[28]. 
P2Y12 inhibitors, clopidogrel, prasugrel, ticagrelor, 
cangrelor
DAPT consisting of aspirin plus clopidogrel has become 
the mainstay of medical therapy for coronary disease after the 
results of the Clopidogrel in Unstable angina to prevent Recur-
rent Events trial, which showed a 20% decrease in composite 
outcome (cardiovascular death, myocardial infarction, stroke) 
using aspirin plus clopidogrel compared to aspirin plus placebo 
in patients with ACS [29]. In addition, the ischemic benefits of 
DAPT were even more defined with regard to reducing the risk 
of stent thrombosis after PCI [30]. Clopidogrel is a prodrug and 
therefore requires two metabolic steps to be converted into its 
active form, which is capable of inhibiting the P2Y12 receptor 
[12,25]. In conjunction, the maximum effects of clopidogrel are 
achieved after 12–24 h, even after a loading dose of 300–600 
mg. The elimination half-life is approximately 4–6 h, although 
the elimination half-life of its active form is much shorter (0.5–1 
h). However, as with aspirin, clopidogrel is able to irreversibly 
inhibit 60–70% of platelet function and the recovery of platelet 
function relies on fresh platelet production from megakaryo-
cytes. The recovery of normal platelet function to normal has 
been demonstrated after 5–7 days of clopidogrel cessation. Be-
cause normal hemostasis does not require the complete recovery 
of platelet function, clinical data regarding surgery have been 
uneventful after 3–5 days of discontinuation [31,32]. Due to its 
pharmacokinetic properties requiring two-step metabolism, 
variable inter-individual responses to clopidogrel have been not-
ed, with 4–34% of patients exhibiting inadequate platelet inhibi-
tory response (i.e., HPR), which is related to adverse ischemic 
outcomes [11].
Similar to clopidogrel, prasugrel requires hepatic activation 
for conversion to its active form. However, the requirement of 
prasugrel for a single-step oxidation process is more efficient, 
yielding 5-fold higher availability of the active metabolite than 
clopidogrel and inhibiting 90% of platelet function [12,25]. This 
pharmacokinetic advantage allows prasugrel to show a rapid 
onset of activity at 0.5–4 h, less inter-individual variability, and 
more consistent platelet inhibition than clopidogrel. Accord-
ingly, accumulating evidence from major clinical trials have 
demonstrated better ischemic efficacy with prasugrel than 
clopidogrel in ACS patients undergoing PCI at the expense of 
increased bleeding risk, which was more serious in patients with 
a previous history of transient ischemic attack or stroke [13]. 
Thus, the 2016 ACC/AHA guidelines recommended that pra-
sugrel be favored over clopidogrel in patients with ACS treated 
with coronary stent but without a history of transient ischemic 
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attack or stroke [18]. The elimination half-life of prasugrel is ap-
proximately 7 h, but as with aspirin and clopidogrel, its inhibi-
tory effect is irreversible. Due to its more complete inhibition of 
platelet function (90%), normalization of platelet function takes 
longer compared to clopidogrel, requiring 7–10 days after dis-
continuation [12].
Unlike clopidogrel and prasugrel, ticagrelor directly inhibits 
the P2Y12 receptor through allosteric modulation [12,25]. There-
fore, ticagrelor does not require hepatic conversion, but its me-
tabolite is also active accounting for 30–40% of its effects. The 
unique pharmacokinetic properties of ticagrelor account for its 
rapid onset of 0.5–4 h, yielding almost complete (90%) inhibi-
tion of platelet function. Its clinical efficacy has also been dem-
onstrated in major clinical trials in ACS patients undergoing ei-
ther PCI or medical therapy, with or without increased bleeding 
risk compared to clopidogrel [14,33]. Thus, the 2016 ACC/AHA 
guidelines recommended that ticagrelor should be favored over 
clopidogrel in patients with ACS treated with a coronary stent 
and in patients with non-ST segment elevation ACS treated with 
medical therapy alone [18]. The antiplatelet effects of ticagrelor 
are reversible with an elimination half-life of approximately 7 h 
requiring twice daily dosing. Complete recovery of platelet func-
tion requires 3–5 days of discontinuation [12]. 
Cangrelor is also an active drug that does not require meta-
bolic activation, and it is the only P2Y12 inhibitor available in 
IV form [12,25]. Because its antiplatelet effect is reversible and 
short-lived with an elimination half-life of 3–5 min, platelet 
function returns to normal within 30–60 min of discontinu-
ation, thus requiring continuous infusion. Accordingly, the 
preoperative administration of cangrelor will not likely pose 
any problems related to bleeding in surgical settings. To date, 
its ischemic benefits have been demonstrated in limited clinical 
studies as an adjunct to DAPT [34]. However, its distinct phar-
macokinetic properties make cangrelor a promising agent for 
bridge therapy before surgery.
GP IIb/IIIa inhibitors, abciximab, eptifibatide, tirofiban
GP IIb/IIIa inhibitors are also available in IV forms and 
target the final common pathway of platelet aggregation [12]. 
Therefore, they constitute the most potent form of antiplatelet 
agent with potential for an unacceptably high risk of bleeding 
when surgery is performed under their influence. The onset of 
these agents is rapid, and the elimination half-life of abciximab 
is 10–30 min, whereas those of eptifibatide and tirofiban are 
2–2.5 h. However, the time of return to platelet function after 
discontinuation is approximately 12 h in abciximab and 4 h in 
eptifibatide and tirofiban. Fortunately, their clinical indications 
are limited to the acute phase of PCI, and no long-term therapy 
with GP IIb/IIIa has been approved. Therefore, their use should 
rarely be encountered in non-cardiac surgery, but more likely 
in the setting of emergent surgical coronary revascularization 
when it is recommended to be stopped for at least 12 h for ab-
ciximab and 2–4 h for eptifibatide and tirofiban. Eptifibatide and 
tirofiban are also promising as bridging agents before surgery.
Non-first-generation DES and New Guidelines 
for the Timing of Non-cardiac surgery
In addition to the advent of novel antiplatelet agents, there 
has also been constant improvement regarding the clinical ef-
ficacy of DES. While previous guidelines regarding the dura-
tion of DAPT after PCI were mostly based on first-generation 
sirolimus- or paclitaxel-eluting stents, evidence regarding the 
use of non-first-generation DES (with elution of everolimus or 
zotarolimus) has emerged [35], forming the basis for the new 
2016 ACC/AHA updated guidelines [18]. Clearly, non-first-gen-
eration DES showed better ischemic protection with less throm-
bogenicity requiring a shorter period for re-endothelialization. 
Accordingly, the necessary duration of DAPT after DES place-
ment has been shortened in the new guidelines [18]. Previously, 
the optimal duration of DAPT after DES placement was 1 year 
and surgery was recommended after this time point. If the risk 
of delaying surgery was greater than the risk of stent thrombosis, 
surgery was recommended after 6 months of DES placement 
[9]. In contrast, the updated 2016 ACC/AHA guidelines recom-
mended elective non-cardiac surgery to be performed 6 months 
after DES placement, and if the risk of delaying surgery was 
greater than the risk of stent thrombosis, surgery could be con-
sidered 3 months after DES placement [18]. Currently, studies 
addressing the efficacies of most recently developed bioabsorb-
able stents, and polymer-free and carrier-free drug-coated stents 
are being performed that may further change the perioperative 
DAPT management.
Bleeding Risk Versus Ischemic Risk and 
Their Consequences
Antiplatelet agents interfere with normal platelet function. 
Therefore, their chronic use is inevitably associated with spon-
taneous bleeding risk. Since the adoption of a lower dosing 
regimen (70–100 mg), spontaneous bleeding risk of aspirin has 
been significantly reduced. Yet, the addition of clopidogrel or 
ticagrelor greatly increased the bleeding risk, which is highest 
with the use of prasugrel [12,13]. In the case of surgery, even 
aspirin monotherapy was associated with a modest increase 
in blood loss, exhibiting a 1.5-fold higher bleeding rate [36]. 
However, the increase in bleeding risk was not associated with 
increased morbidity or mortality, except in intracranial surgery 
[37]. The results of the PeriOperative ISchemic Evaluation 2, 
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aspirin arm (POISE-2, ASA) trial, which was conducted in 
patients undergoing noncardiac surgery, should be mentioned 
as it showed increased risk of major bleeding related to aspirin 
monotherapy in non-cardiac surgery without any increase in the 
risk of adverse outcome, while no ischemic benefit was observed 
[38]. However, only 23% of the patients included in the trial had 
a history of coronary artery disease, and 4.7% received PCI. In 
this study, aspirin was randomized to patients at risk for vascular 
complications and not to patients receiving aspirin specifically 
for secondary prevention of known cardiovascular disease.
Although evidence regarding the interruption of aspirin 
therapy administered for secondary prevention is mostly lim-
ited to observational studies, a meta-analysis involving 50279 
patients receiving aspirin for this purpose revealed a few impor-
tant results that should be taken into consideration when tailor-
ing perioperative DAPT [39]. First, the cardiac complication 
rate was increased by 3-fold after aspirin withdrawal, which was 
unacceptably higher (90-fold increase) in patients who received 
coronary stents. Second, the average time interval from aspirin 
cessation to coronary events was 8.5 days [36,39]. These results 
and those of other case reports suggest that aspirin therapy for 
secondary prevention of cardiovascular events should be in-
definite, whenever possible, and extreme caution should be ex-
ercised when it is stopped for more than 8 days. Concerns have 
also been raised with regard to rebound hypercoagulability after 
aspirin withdrawal by excessive thromboxane A2 activity and 
decreased fibrinolysis, all of which could be further aggravated 
by surgery-related acute phase reaction [6]. Therefore, the peri-
operative course may not allow for a time interval of 8.5 days.
This could be more problematic with DAPT, particularly after 
PCI. Current evidence regarding the bleeding risk of DAPT 
stems mostly from cardiac surgery and is limited to small num-
bers of studies or case series in non-cardiac surgery [40]. Over-
all, the increase in bleeding associated with DAPT in cardiac 
surgery seems to be 30–50% with increased morbidity (reop-
eration rate) [41]. However, when non-cardiac surgery is per-
formed during the early re-endothelialization phase after PCI, 
the rate of myocardial infarction increased steeply to an average 
of 30% reaching a high mortality of 20–86% [42,43]. Account-
ing for these results, the overall clinical consequences of DAPT 
cessation during the early re-endothelialization phase after PCI 
seem to be far more serious than the bleeding risk it accompanies. 
Role of Platelet Function Tests and the 
Search for an Optimal Therapeutic Window
As mentioned above, clopidogrel, currently the main P2Y12 
inhibitor used as a DAPT, exhibits considerable inter-individual 
variability in the platelet inhibitory response [10]. In conjunc-
tion, many observational studies in the PCI setting reported 
robust correlations between HPR measured by various platelet 
function tests and adverse ischemic outcomes [11]. However, 
evidence regarding the opposite end of platelet reactivity (i.e., 
low platelet reactivity) and its association with increased risk of 
bleeding is limited. Moreover, there have been no randomized, 
controlled trials showing any clinical improvement upon modi-
fying the antiplatelet regimen according to the results of platelet 
function tests or genetic testing [18]. In the surgical setting, 
evidence regarding the use of platelet function tests is mostly 
limited to cardiac surgeries. Accumulating evidence suggests the 
usefulness of various platelet function tests in predicting blood 
loss related to DAPT [44,45]. Overall, the preoperative platelet 
function tests seem to have higher negative predictive value than 
positive predictive value, meaning that patients found to have 
normal platelet function (or HPR to P2Y12 inhibitors) do not 
exhibit increased bleeding risk compared to those not exposed 
to DAPT [46]. This observation seems logical as perioperative 
bleeding stems from multifactorial factors. In conjunction, the 
use of platelet function tests has been incorporated into recent 
guidelines on the use of antiplatelet agents in cardiac and non-
cardiac surgery as a class IIb recommendation [46].
Notwithstanding the potential importance of platelet func-
tion tests, several limitations must be taken into consideration 
in their clinical application. First, there are numerous platelet 
function tests (PFA-100, VerifyNow, TEG-PM, Multiplate, and 
so forth) with various and different cut-off values. Second, no 
platelet function test can provide an optimal therapeutic window 
of platelet reactivity to P2Y12 inhibitors associated with minimal 
bleeding as well as ischemic risk. Third, evidence to recommend 
platelet function tests in non-cardiac surgeries is scarce. At pres-
ent, the role of platelet function tests in the perioperative period 
is limited to determining the optimal safe timing of surgery 
without increasing bleeding risk related to DAPT by demonstra-
tion of normal platelet function (or HPR) or guiding platelet 
transfusion in bleeding patients [46,47]. The search to overcome 
the abovementioned limitations should be continued to enable 
tailored perioperative DAPT aimed at providing an optimal 
therapeutic window based on clear-cut criteria. 
Potential bridge Therapy to Surgery
The rationale and necessity of bridge therapy to prevent stent 
thrombosis without the added burden of increased periopera-
tive blood loss is indisputable. Safe bridge therapy has become 
feasible with the advent of different classes of rapid-onset, short-
acting, reversible, and IV forms of antiplatelet agents. Without 
solid evidence, heparin (either unfractionated or low-molecular-
weight) has been suggested as a bridge; however, arterial throm-
bosis is more dependent on the activation of platelets than the 
coagulation cascade [1]. Moreover, concerns have been raised 
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regarding the potential harm of unfractionated heparin expos-
ing the platelets to activation by adenosine diphosphate and 
actually augmenting thrombosis formation [48].
Although few in number, clinical studies using a GP IIb/IIIa 
inhibitor (tirofiban, eptifibatide) as a bridge has shown promis-
ing results [15], while another study in 67 patients undergoing 
mostly non-cardiac surgery indicated acute ST changes in two 
patients occurring in the immediate postoperative period [49]. 
With regard to cangrelor, a recent bridging antiplatelet therapy 
with cangrelor in patients undergoing cardiac surgery trial in-
volving 210 patients with ACS or recent PCI undergoing surgi-
cal coronary revascularization showed consistent maintenance 
of platelet inhibition with cangrelor without any increase in 
major bleeding events [16]. More recently, a systematic review 
of clinical trials and case series of bridge therapy involving 420 
patients depicted overall freedom from ischemic events and 
bleeding/transfusion in 96.2% and 72.6% of the patients, respec-
tively [50]. The median period after PCI (mostly DES place-
ment) upon surgery ranged from 2 to 14 months, with most 
of the studies showing a period of 2–6 months. Thus, although 
both agents showed promise, additional evidence regarding the 
clinical efficacy of both GP IIb/IIIa inhibitors and cangrelor as a 
bridge for discontinuation of a P2Y12 inhibitor in patients at risk 
for stent thrombosis is required. Of note, only clopidogrel was 
discontinued and aspirin was continued in all of the clinical tri-
als addressing the efficacy of bridge therapy.
Recommendations on Perioperative DAPT 
Management for Non-cardiac Surgery
Based on current evidence, it seems imperative to delay sur-
gery after PCI during the re-endothelialization period, which 
would be 14 days after ballooning, 30 days after bare metal stent 
placement, and at least 3 months (preferentially 6 months) after 
DES placement [18]. After this period, it is generally recom-
mended that the P2Y12 inhibitor be stopped for the necessary 
duration to allow platelet function recovery (clopidogrel, 5–7 
days; prasugrel, 7–10 days; ticagrelor, 3–5 days) and that aspirin 
be continued, except for intracranial procedures when aspirin 
cessation may be considered for 3–4 days prior to surgery. The 
duration of P2Y12 inhibitor discontinuation may also be guided 
by platelet function tests, which may be helpful in avoiding un-
necessary delay of surgery by confirming platelet functional 
recovery regardless of the discontinuation date, particularly 
with clopidogrel. In emergent or urgent surgeries that cannot be 
delayed beyond the recommended period after PCI, proceed-
ing to surgery with continued DAPT should be considered as 
the risk and clinical consequences of stent thrombosis are far 
greater than the risk of bleeding. For intracranial procedures or 
other selected surgeries in which increased bleeding risk may 
also be fatal, cessation of DAPT (possibly with continuation or 
minimized interruption [3–4 days] of aspirin) with potential 
bridge therapy using cangrelor or GP IIb/IIIa inhibitors may be 
contemplated. In cases of non-surgical bleeding with continua-
tion of aspirin or DAPT, platelet function test may be performed 
to guide transfusion of platelet concentrates. Regardless of the 
elapsed time of surgery after PCI, DAPT should be restarted in 
the postoperative period as soon as possible for the originally in-
tended duration. It is important to make a consensus regarding 
perioperative DAPT among the anesthesiologist, cardiologist, 
surgeon, and patient as well for the common goal of minimizing 
both ischemic and bleeding risks (Table 2).
Table 2. Recommendations on Perioperative Dual Antiplatelet Therapy for Non-cardiac Surgery after Percutaneous Coronary Intervention
Recommendations
Patient-based tailored consensus decision among the anesthesiologist, cardiologist, surgeon, and the patient for the common goal of minimizing 
both ischemic and bleeding risks
Elective surgery
    After balloon angioplasty: delay for 14 days
    After bare-metal stent placement: delay for 30 days
    After drug-eluting stent placement: delay for 6 months (3 months is acceptable, if further delay is not feasible)
Surgery after the re-endothelialization period
    Continue aspirin, whenever possible (except for intracranial surgery, consider discontinuation for 3–4 days)
    Discontinue P2Y12 inhibitor, if necessary (clopidogrel 5–7 days, prasugrel 7–10 days, ticagrelor 3–5 days) 
    Platelet function test may be considered to determine the optimal timing of surgery after discontinuation
Emergent or urgent surgery during the re-endothelialization period
    Consider continuation of dual antiplatelet therapy
    In surgeries with serious bleeding risk, consider continuation of aspirin (or 3–4 days of cessation, if necessary) and discontinuation of oral P2Y12 
      inhibitors with bridge therapy using cangrelor, tirofiban, or eptifibatide
In cases of non-surgical bleeding, platelet function test may be performed to guide platelet transfusion 
Restart dual antiplatelet therapy as soon as possible following surgery for the intended duration after percutaneous coronary intervention
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Conclusions
Technical advances related to coronary stents and antiplatelet 
agents are continuously evolving with the reporting of relevant 
clinical evidence. While there are numerous guidelines, many 
challenging clinical situations require a consensus decision 
based on the expert opinions of the attending physicians. There-
fore, a comprehensive understanding regarding the pharmacol-
ogy of novel antiplatelet agents and their clinical applicability, 
the clinical efficacies of the newer coronary stents and their risk 
of stent thrombosis, and the role of platelet function tests must 
be determined. Incorporating such information, the goal of 
perioperative management of DAPT in patients with ACS, treat-
ed either with or without PCI, should be set to provide optimal 
tailored management.
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